Pasithea Therapeutics (KTTA) FCF Margin (2022)
Pasithea Therapeutics (KTTA) posted FCF Margin of 1361.84% for Q4 2022, up 35.66% sequentially from 2116.61% in Q3 2022.
Pasithea Therapeutics (KTTA) FCF Margin (2022) Analysis & Trends
Pasithea Therapeutics has reported FCF Margin for 1 years, with the latest figure at 1361.84% in Q4 2022.
- Quarterly FCF Margin changed N/A year-over-year to 1361.84% in Q4 2022, while the trailing twelve-month figure through Dec 2022 was 2466.64% (changed N/A YoY) and the FY2022 annual result came in at 2466.64%, up 1874941.0% from the prior year.
- FCF Margin advanced to 1361.84% in Q4 2022 per KTTA's latest filing, from 2116.61% in the prior quarter.
- Over five years, FCF Margin peaked at 1361.84% in Q4 2022 and troughed at 15771.77% in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.69 Bn | 130.84 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.29 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.79 Bn | 59.60 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.44 Bn | 54.31 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.92 Bn | 27.61 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 28.10 Bn | 9.71 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.33 Bn | 26.17 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 70.82% |
| 10 | Pasithea Therapeutics | 15.55 Mn | 15.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -1,361.84% |
| Sep 30, 2022 | -2,116.61% |
| Jun 30, 2022 | -14,302.08% |
| Mar 31, 2022 | -15,771.77% |